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Tear Osmolarity and Dry Eye Symptoms in Women Using Oral
Contraception and Contact Lenses
Abstract
Purpose—To examine the relationship between oral contraceptive pill (OCP) use, contact lens wear, and dry
eye signs and symptoms in healthy young females.
Methods—Fifty-two women using OCPs and forty-five women not using any form of hormonal
contraception were enrolled. Medical, menstrual, and contact lens histories were obtained and dry eye
symptoms were assessed using the Ocular Surface Disease Index (OSDI) and Symptom Assessment iN Dry
Eye (SANDE) questionnaires. Tear osmolarity testing was performed using the TearLab™ Osmolarity System.
Results—Mean age of all subjects was 26.0 ± 3.7 years. There were no significant differences in any of the
measurements between the follicular and luteal phases. While SANDE scores were significantly higher in
subjects with OCP and recent contact lens use (p<0.01), there were no significant differences in OSDI and
tear osmolarity amongst the same subject groups. Subjects who reported both OCP and recent contact lens
use had significantly higher OSDI and SANDE scores (p=0.015 and p<0.001, respectively).
Conclusions—There were no differences between the phases of the menstrual cycle. Tear osmolarity was not
affected by OCP or contact lens use in young females. However, the combination of OCP use and contact lens
wear may increase the severity of dry eye symptoms.
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Abstract
Purpose—To examine the relationship between oral contraceptive pill (OCP) use, contact lens
wear, and dry eye signs and symptoms in healthy young females.
Methods—Fifty-two women using OCPs and forty-five women not using any form of hormonal
contraception were enrolled. Medical, menstrual, and contact lens histories were obtained and dry
eye symptoms were assessed using the Ocular Surface Disease Index (OSDI) and Symptom
Assessment iN Dry Eye (SANDE) questionnaires. Tear osmolarity testing was performed using
the TearLab™ Osmolarity System.
Results—Mean age of all subjects was 26.0 ± 3.7 years. There were no significant differences in
any of the measurements between the follicular and luteal phases. While SANDE scores were
significantly higher in subjects with OCP and recent contact lens use (p<0.01), there were no
significant differences in OSDI and tear osmolarity amongst the same subject groups. Subjects
who reported both OCP and recent contact lens use had significantly higher OSDI and SANDE
scores (p=0.015 and p<0.001, respectively).
Conclusions—There were no differences between the phases of the menstrual cycle. Tear
osmolarity was not affected by OCP or contact lens use in young females. However, the
combination of OCP use and contact lens wear may increase the severity of dry eye symptoms.
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INTRODUCTION
Dry eye disease (DED or keratoconjunctivitis sicca) is a common multifactorial disease of
the tears and the ocular surface that can significantly diminish visual function and quality of
life. It is one of the leading causes of patient visits to ophthalmologists and optometrists in
the United States and is estimated to affect 5-35% of the population.1,2 DED predominantly
affects women, raising the question regarding estrogen’s role in DED.1,2 However, the
relationship between DED and estrogen is complex as it is associated with both low and
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high estrogen states, leading investigators to consider the influence of not only estrogen but
also of androgen and other sex hormones in the pathophysiology of DED.3,4
While the influence of androgens may account for most of the sex-related differences found
in the lacrimal tissue, the effects of estrogen are still unclear and the evidence regarding its
role is often conflicting.3 Estrogen is known to cause a decrease in lipid production and size
of sebaceous glands in general.5 Thus, one could speculate that dry eye symptoms would be
more severe during states of increased estrogen, such as in pregnancy or hormonal
contraceptive use. Yet, despite the widely held clinical perception that the use of hormonal
contraceptives may be associated with dry eye symptoms, there are surprisingly few studies
examining this relationship.6-8
In addition to the complex influence of hormones on DED, contact lens wear is another
common cause of DED. Of the more than 125 million contact lens wearers worldwide, as
many as 80% report occasional to frequent dry eye symptoms.9,10 In an era of increasing
contact lens and hormonal contraceptive use, some clinicians have noted increased contact
lens intolerance in women using OCPs.11-14 However, very few studies have attempted to
elucidate the relationship between hormonal contraceptive use, contact lens wear and dry
eye.13,15
In recent years, evidence has emerged supporting the use of tear osmolarity testing as a
potentially useful global marker for DED that is elevated in both evaporative and aqueous
tear-deficient subtypes of DED.16-18 The 2007 amended definition for dry eyes states that
tear film instability and hyperosmolarity are core mechanisms of dry eye pathology.2 The
purpose of this study was to examine the relationships among tear osmolarity, dry eye
symptoms, contact lens wear, and oral contraceptive pill use in young women.
METHODS
Subjects
Subjects enrolled were students, employees, and patients at the University of Pennsylvania.
The study was approved by the University’s Institutional Review Board and conducted in
accordance with the University’s guidelines for experimental investigation with human
subjects. Informed consent was obtained from each participant prior to starting study
procedures.
Eligible subjects were females between the ages of 18 and 40 years. Eligible subjects were
required to be either using oral contraceptive pills currently and during the previous three
months (OCP+ group) or not having used any form of hormonal birth control for at least one
week (OCP- group). Subjects in the OCP- group needed to have reported regular menstrual
cycles lasting between 21 and 35 days. Subjects were excluded if they were currently
pregnant, used ophthalmic drops within two hours of the study visit, or had a history of
ocular inflammation in the past three months, ocular surgery in the past six months, or an
autoimmune disease (i.e., Rheumatoid arthritis, Lupus, sarcoidosis, or Sjögren’s syndrome).
All subjects completed a study visit to provide a medical history, complete questionnaires on
DED symptoms, and have measurements of tear osmolarity. Subjects in the OCP- group
completed a second visit. The two visits were approximately two weeks apart, depending on
the reported length of the subject’s menstrual cycle, to capture measurements from both the
follicular and luteal phase of the cycle.
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History
Demographic information, contact lens wear, ocular history, past medical and surgical
history, current systemic and ophthalmic medications, and menstrual cycle information were
obtained by patient self-report. Day of ovulation was calculated by subtracting 14 days from
the reported menstrual cycle length. The follicular phase was defined as the days before
ovulation and the luteal phase as those following ovulation. Contact lens history was
recorded as contact lens use in the past 30 days (CL30+/-), contact lens wear during the
study visit (CLvisit+/-), and any history of contact lens use. The frequency of contact lens use
in the past 30 days and the time since first contact lens use were also recorded.
Assessments of Dry Eye Disease
Dry eye symptoms were assessed using the Ocular Surface Disease Index (OSDI; Allergan,
Inc, Irvine, CA) and the Symptom Assessment iN Dry Eye (SANDE; Daiichi
Pharmaceutical Corporation, Montvale, NJ) questionnaires.19,20 The OSDI consists of 12
questions on symptoms within the past week and yields scores ranging from 0 (least severe)
to 100 (most severe). The SANDE consists of two questions, one on average frequency and
the other on average severity of symptoms, with responses recorded on a visual analogue
scale ranging from 0 to 100 millimeters. Tear osmolarity measurements were obtained from
each eye using the TearLab™ Osmolarity System (TearLab, San Diego, CA). Subjects were
instructed not to rub their eyes for at least 10 minutes. Tear samples were collected by
placing the tip of the TearLab device gently at the inferior lateral tear meniscus with care
being taken not to induce reflex tearing. At the beginning of each day of patient testing, the
TearLab™ Osmolarity System was calibrated in accordance with the manufacturer’s
instructions. All measurements were performed by the same investigator. Since inter-eye
variability has been found to be associated with an increased severity of DED, the
measurement from the eye with the higher osmolarity was used for data analysis.17
Statistical Analysis
Differences in demographics were analyzed using Student t-test for continuous measures
and Fisher’s exact test for categorical factors. Differences in outcome measures between the
follicular and luteal menstrual phases were assessed by paired t-tests using data only from
the 29 patients who had measurements taken during both phases. Only the values from the
first visit were used for all other analyses. Differences in measurements between two groups
were assessed with t-tests for tear osmolarity and with Wilcoxon rank sums tests for the
questionnaire scores. Bootstrapping with 2000 repetitions and using bias-corrected
percentiles was used to generate 95% confidence intervals for the median differences
between questionnaire scores. Differences among the four groups were assessed with one-
way analysis of variance (ANOVA) for the tear osmolarity measurement and the Kruskal-
Wallis test for the OSDI, SANDE severity, and SANDE frequency scores. Additionally,
using the recently published cut-off point of 308 mOsm/L, differences in high versus low
tear osmolarity between groups were assessed using Fisher’s exact tests.17 Spearman rank-
order correlation coefficients were used to examine the pairwise relationships.
RESULTS
All subjects
One hundred female subjects were enrolled in the study. Three subjects were excluded due
to a menstrual cycle length greater than 35 days for the cycle observed, resulting in 52
subjects in the OCP+ group and 45 in the OCP- group. Among the 97 subjects, 48 (49%)
wore contact lenses in the past 30 days (CL30+). One subject carried a DED diagnosis and
fifteen (15%) reported suffering from “dry eye symptoms” in the ocular history. Overall,
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self-reported histories revealed a healthy study population; 95% and 86% of all subjects had
no ocular and medical history, respectively, and 67% of subjects had not taken any
medication (e.g., nasal or inhaled steroids, antihistamines, or antidepressants) in the past 30
days. The distribution of age and race, stratified by oral contraceptive pill use and by contact
lens wear, is summarized in Table 1.
Women in the OCP+ group were on average 2.1 years older (p<0.005) than women in the
OCP- group. There were significant differences in the race distribution between the OCP+
and OCP- groups. (p=0.03). Notably, there were more Caucasians and less African-
American women in the OCP+ group. However, upon further stratified sub-analysis, race
did not appear to be responsible for differences in scores between the OCP groups. The
women in the OCP+ groups were taking nineteen different brands of OCP; eighteen were
combined estrogen-progesterone pills and one was progesterone-only. The six forms of
progesterone were desogestrel, levonorgestrel, norethindrone acetate, drospirenone,
norgestimate and ethynodiol diacetate. The average menstrual cycle length in the OCP-
group was 29.1 ± 2.6 days.
There were no significant age differences between women who had worn contact lenses in
the past 30 days (CL30+) and those who had not (CL30-). However, there were significantly
more Caucasian and Asian women and less Black women in the CL30+ group (p=0.002).
Upon further analysis, race did not appear to be responsible for differences in the CL30
groups. Sixty percent of the CL30+ subjects and 45% of the CL30- subjects were taking
OCPs.
Overall, OSDI correlated well with both SANDE severity (data not shown; ρ=0.53,
p<0.0001) and frequency (data not shown; ρ=0.63, p>0.0001). However, OSDI and tear
osmolarity were not correlated (ρ=-0.03, p=0.80).
Oral contraceptive pill use
Among the 29 OCP- subjects with measurements taken from both the follicular and luteal
phase, the mean values for the assessments of dry eye disease were slightly worse during the
follicular phase, but none of the differences were statistically significant (Table 2).
Therefore, only measurements from the initial study visit were used for all other analyses.
Table 3 summarizes the results for each group. Between the OCP+ and OCP- subjects, the
SANDE severity and frequency scores were significantly worse in the OCP+ subjects
(p=0.01 and 0.007, respectively).
However, there were no significant differences in tear osmolarity and OSDI (p>0.25 for
both). Similarly, the proportion of subjects with tear osmolarity >308 mOsm/L was similar
in the OCP+ (27%) and OCP- (24%) groups (data not shown; p=0.78). The amount of
estrogen in the OCPs (ranging from 0.020 mg to 0.035 mg) was analyzed as a continuous
variable using Spearman correlations. Estrogen dose did not correlate with tear osmolarity
(ρ=-0.09 p=0.52) or symptom scores (OSDI ρ=0.04, p=0.78; SANDE severity ρ =0.09,
p=0.50; SANDE frequency ρ=-0.03, p=0.82).
Contact lens wear
Within the CL30+ group, nearly all (98%) wore soft contact lenses. Thirty-eight (79%) had
“consistent” (>50 hours per week) or “moderate” (30-50 hours per week) contact lens wear
on average and the mean time since first contact lens wear was 10.83 ± 3.97 years for these
38 subjects. Thirty-four (89%) of the 38 subjects in this group were wearing contact lenses
during the study visit (CLvisit+). Table 3 provides a summary of the measurements of dry
eye for the different contact lens groups. Among CL30+, SANDE scores for severity and
frequency were significantly higher (p=0.002 and p<0.0001, respectively) but tear
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osmolarity and OSDI score were not. Among CLvisit+ subjects, the mean tear osmolarity and
SANDE scores were significantly higher than among CLvisit- subjects
Oral contraceptive pill use and contact lens wear
When women were classified simultaneously by OCP use and contact lenses wear within the
past 30 days, women with both factors had the highest median score on the SANDE severity
and frequency questions, those with neither had the lowest and those with one factor had
intermediate values (Table 4; p<0.001 for both SANDE scores). Subjects with both OCP and
contact lens wear within the past 30 days had the highest median OSDI score of all groups
(p=0.015). Tear osmolarity did not differ among the groups (p=0.403 by ANOVA; p=0.592
by Kruskal-Wallis test).
DISCUSSION
Sex hormones and dry eye
Sex hormones appear to influence structural and functional aspects of the eye and contribute
to ocular surface disorders such as DED and Sjögren’s syndrome.3,5 The female menstrual
cycle provides an opportunity to study changes resulting from the ebb and flow of sex
hormones such as estrogen and progesterone. Typically, in a normal menstrual cycle, the
follicular phase (day 1-14) is marked by low levels of progesterone and a gradual rise in
estrogen, ovulation occurs mid-cycle (day 13-16) after the estrogen peak, and the luteal
phase is marked by rising progesterone levels and a less steep rise in estrogen levels.
Hormonal contraceptives, most commonly combined synthetic estrogen and progesterone,
work by inhibiting ovulation.21
Studies evaluating ocular changes over the menstrual cycle are few in number and most
draw findings from a limited number of subjects. 6,22-25 A recent study analyzing dry eye
symptoms over the normal menstrual cycle reported worsening of ocular surface parameters
related to eye dryness and inflammation during the follicular phase, especially in dry eye
patients; however, subjective dry eye symptoms increased during the luteal phase, which
they attributed to the ‘premenstrual syndrome’ (PMS).23 Central corneal thickness appears
to increase around ovulation and the end of the menstrual cycle, both of which occur after
estrogen peaks.6,24
While some authors have found subjective dry eye symptoms and tear production and
stability to be significantly related to hormonal fluctuations in the menstrual cycle, our study
found no significant differences between the follicular and luteal phases of the menstrual
cycle.23 Tomlinson et al likewise found no significant differences in tear film parameters
and dry eye symptoms between the follicular and luteal phases in their small study
population.8 The follicular and luteal study visits for control subjects occurred at different
points across the respective phases and hence, data may have been captured from a
continuum of hormonal fluctuations as opposed to hormonal peaks and troughs.
Furthermore, the normal menstrual cycle exhibits variations in cycle length.26 Relative
estrogen and progesterone levels were based on normal menstrual cycle physiology; we did
not perform serum hormone testing to confirm levels.
Effect of oral contraceptive pill use on dry eye
In this study, neither OCP use nor estrogen dose of OCPs appeared to have a meaningful
effect on tear osmolarity and dry eye symptoms as measured by OSDI. However, OCP use
was associated with significantly higher SANDE scores as well as a greater number of
subjects reporting dry eye symptoms in the ocular history. Though the OCP+ group was
significantly older than the OCP- group, the age difference is unlikely to account for
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differences in the SANDE scores. For the most part, dry eye prevalence increases with age,
but most large population-based studies of dry eye have been in the over 50 population and
few have examined prevalence in individuals under 40 years of age.2 Race differences also
do not appear to be responsible for differences in scores. Though the effect of race or
ethnicity on DED is unclear, limited data in the literature suggests that the prevalence of dry
eye symptoms among women is higher in Hispanics and Asians when compared to
Caucasians.27
Our finding that OCPs did not significantly affect tear osmolarity is consistent with other
reports in the literature. For example, other authors have reported no difference in Schirmer
I and tear break-up time (TBUT) results between women using OCP and controls.7 In
addition, Tomlinson et al found no significant differences in tear osmolality, pre-rupture
phase time, evaporation rate, turnover rate, or volume between OCP users and controls or
between the follicular and luteal phases.8
Effect of contact lens wear on dry eye
While the exact mechanism of contact lens-associated dry eye is unclear, contact lenses have
been proposed to cause inflammation, meibomian gland dysfunction, corneal
hyposensitivity, or a combination which results in decreased tear production, increased
evaporation, and subsequent tear film hyperosmolarity.15,28-33
Although 48% of CL30+ subjects compared to 22% of CL30- subjects reported
experiencing dry eyes in the past 30 days (data not shown; p=0.01) and CL30+ subjects
reported significantly higher SANDE scores, the OSDI and tear osmolarity measurements
did not detect a significant difference. Only 25% of the CL30+ subjects and 29% of CLvisit+
subjects had dry eye symptoms characterized by an OSDI score >13, the cutoff for mild dry
eye.44 This rate of dry eye is much lower than the 50-80% reported by studies using self-
reported dry eye surveys such as the Contact Lens Dry Eye Questionnaire.9,10,15,34
However, in two of these survey studies, the mean age of contact lens wearers was
approximately 13 years older than subjects in our study.9,10 Since dry eye prevalence
increases with age, this could partially explain the difference in dry eye rates between the
current study and earlier studies.2 Designed as a disease specific questionnaire, the OSDI
would be expected to capture complaints of dry eye (i.e., eyes that feel gritty, painful or
sore) associated with contact lens wear. 19
Earlier studies characterizing tear osmolarity require contact lenses to be removed prior to
the measurement; we chose to capture real-time tear osmolarity measurements during
contact lens wear and did not ask subjects to remove their contact lenses at
testing.15,17,18,28,29,35 Tear sampling was performed at the lateral meniscus and care was
taken not to perturb the contact lens or induce reflex tearing. We found that the mean tear
osmolarity was the same for all subjects not wearing contact lenses during the study visit,
regardless of their history of contact lens wear in the past 30 days. Subjects who were
wearing contact lenses during the study visit had a mean tear osmolarity 5.8 mOsm/L higher
than either the CL30- or CL30+/CLvisit- groups (p=0.054), thus supporting the notion that
the presence of contact lenses alters tear film physiology.
Effect of oral contraceptive pill use and contact lens wear on dry eye
Though median OSDI scores were not significantly higher for subjects with OCP use or
contact lens wear within the past 30 days, OSDI was significantly higher in subjects with
both factors. This is consistent with the belief that oral contraceptives may increase contact
lens intolerance, an idea supported by an early paper demonstrating that contact lens
wearing females with OCP use are almost twice as likely to report dry eye symptoms as
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contact lens wearing females without OCP use.11 However, previous studies examining this
relationship were conducted more than three decades ago and therefore, do not reflect the
effects of modern contact lenses and OCPs.11-14 The overall lack of correlation between
OSDI and tear osmolarity in this study adds further evidence supporting the poor
relationship between dry eye signs and symptoms.36
Limitations
Potential limitations of the study include the fact that we did not control for different OCP
types, contact lens materials, contact lens wear patterns and duration, diurnal variations,
climate, and environmental stress. In addition, findings from a recent study indicate that
TearLab osmolarity measurements have wide variation and recommended averaging three
consecutive measurements to obtain a more reliable value.37 In our study, tear osmolarity
was checked only once in each eye at each study visit. Future studies, which use three
consecutive measurements per eye, may yield results different from ours.38 Finally, this
study was designed to assess subjective symptoms and one objective dry eye marker—tear
osmolarity, which has been reported to exhibit better sensitivity and/or specificity as well as
less variability than common dry eye tests such as corneal staining, meibomian gland
grading, TBUT, and Schirmer’s.17,38 As such, we did not perform a comprehensive clinical
exam to assess DED status or sub-type during the study visits.
Conclusions
The evidence surrounding the role of sex hormones in dry eye disease is unclear and at
times, contradictory. In this study, we hoped to better elucidate the effect of sex hormones in
dry eye disease by studying differences in 1) the normal menstrual cycle phases of healthy
young women and 2) women using and not using OCPs. We did not find significant
differences in tear osmolarity among any of our comparison groups. Interestingly, by not
excluding contact lens wear, our results demonstrated a possible synergistic effect of OCP
use and contact lens wear in exacerbating dry eye symptoms. Further studies need to be
performed to better characterize this relationship and to study the utility of tear osmolarity
measurements in clinical practice.
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Table 2
Differences, follicular minus luteal phase measurements, in dry eye assessments among subjects not taking
oral contraceptives
Difference Mean ± SD p-value
Tear osmolarity (mOsm/L) 2.3 ± 15.9 0.43
Ocular Surface Disease Index score 0.4 ± 5.8 0.74
Symptom Assessment iN Dry Eye severity score 0.7 ± 8.8 0.69
Symptom Assessment iN Dry Eye frequency score 1.2 ± 8.7 0.48
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